Preformed, high-titer anti-human leukocyte antigen (HLA) antibodies remain a major barrier to successful kidney transplantation, increasing the risk of early graft loss and prolonged time on dialysis. Despite advances in desensitization, current therapies are largely ineffective for patients with extremely high antibody levels.
Kidney International published a clinical update in Research Highlights on 13 Feb 2026.
The item focuses on B-cell maturation antigen-Targeted T-cell Engager Therapy Combined with B-cell Depletion for Treatment of Refractory HLA Sensitization.
Review the original article for the full source wording and details.